Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message

Login Alert

Cancel
Log in
×
×
Register
Log In
(0) Cart
Logo for Cambridge Core from Cambridge University Press. Click to return to homepage.
Logo for Cambridge Core from Cambridge University Press. Click to return to homepage.
Cited by
  • Crossref logo 6
  • Google Scholar logo
Crossref Citations
Crossref logo
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Toy, Mehlika 2013. Cost-effectiveness of viral hepatitis B & C treatment. Best Practice & Research Clinical Gastroenterology, Vol. 27, Issue. 6, p. 973.
  • CrossRef
  • Google Scholar
La Torre, Giuseppe Mannocci, Alice Saulle, Rosella Colamesta, Vittoria Meggiolaro, Angela Mipatrini, Daniele and Sinopoli, Alessandra 2016. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013). Human Vaccines & Immunotherapeutics, Vol. 12, Issue. 9, p. 2299.
  • CrossRef
  • Google Scholar
Goyal, Ashish and Murray, John M. 2016. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication. Theoretical Population Biology, Vol. 112, Issue. , p. 60.
  • CrossRef
  • Google Scholar
Rognoni, Carla Ciani, Oriana Sommariva, Silvia and Tarricone, Rosanna 2017. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value in Health, Vol. 20, Issue. 3, p. 336.
  • CrossRef
  • Google Scholar
Coste, Marion De Sèze, Maëlle Diallo, Aldiouma Carrieri, Maria Patrizia Marcellin, Fabienne and Boyer, Sylvie 2019. Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). BMJ Open, Vol. 9, Issue. 7, p. e030211.
  • CrossRef
  • Google Scholar
Wigfield, Peter Sbarigia, Urbano Hashim, Mahmoud Vincken, Talitha and Heeg, Bart 2020. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. PharmacoEconomics - Open, Vol. 4, Issue. 3, p. 403.
  • CrossRef
  • Google Scholar
Google Scholar Citations

View all Google Scholar citations for this article.

×
Cambridge University Press

Our Site

  • Accessibility
  • Contact & Help
  • Legal Notices

Our Platforms

  • Cambridge Core
  • Cambridge Open Engage
  • Cambridge Higher Education

Our Products

  • Journals
  • Books
  • Elements
  • Textbooks
  • Courseware

Join us online

Please choose a valid location.

  • Rights & Permissions
  • Copyright
  • Privacy Notice
  • Terms of Use
  • Cookies Policy
Cambridge University Press 2025

Cancel
Confirm
×

Save article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE?
  • Volume 29, Issue 1
  • Frank Hulstaert (a1), Christoph Schwierz (a1), Frederik Nevens (a2), Nancy Thiry (a1), Mohamed Gamil (a2), Isabelle Colle (a3), Stefaan Van de Sande (a1) and Yves Horsmans (a4)
  • DOI: https://doi.org/10.1017/S0266462312000736
Please provide your Kindle email.
Available formats Please select a format to save.
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE?
  • Volume 29, Issue 1
  • Frank Hulstaert (a1), Christoph Schwierz (a1), Frederik Nevens (a2), Nancy Thiry (a1), Mohamed Gamil (a2), Isabelle Colle (a3), Stefaan Van de Sande (a1) and Yves Horsmans (a4)
  • DOI: https://doi.org/10.1017/S0266462312000736
Available formats Please select a format to save.
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE?
  • Volume 29, Issue 1
  • Frank Hulstaert (a1), Christoph Schwierz (a1), Frederik Nevens (a2), Nancy Thiry (a1), Mohamed Gamil (a2), Isabelle Colle (a3), Stefaan Van de Sande (a1) and Yves Horsmans (a4)
  • DOI: https://doi.org/10.1017/S0266462312000736
Available formats Please select a format to save.
×
×

Reply to: Submit a response

Contents help
Close Contents help

- No HTML tags allowed
- Web page URLs will display as text only
- Lines and paragraphs break automatically
- Attachments, images or tables are not permitted

Please enter your response.

Your details

Email help
Close Email help

Your email address will be used in order to notify you when your comment has been reviewed by the moderator and in case the author(s) of the article or the moderator need to contact you directly.

Please enter a valid email address.
You have entered the maximum number of contributors

Conflicting interests

Do you have any conflicting interests? * Conflicting interests help

Close Conflicting interests help

Please list any fees and grants from, employment by, consultancy for, shared ownership in or any close relationship with, at any time over the preceding 36 months, any organisation whose interests may be affected by the publication of the response. Please also list any non-financial associations or interests (personal, professional, political, institutional, religious or other) that a reasonable reader would want to know about in relation to the submitted work. This pertains to all the authors of the piece, their spouses or partners.